论文部分内容阅读
目的观察围手术期不同剂量瑞舒伐他汀对老年急性非ST段抬高心肌梗死(NSTEMI)患者PCI术后影响。方法将156例需行择期PCI的老年NSTEMI患者随机分成常规剂量组(10mg/d,A组)和大剂量组(20mg/d,B组)各78例,在服药前、PCI术前及术后24h、1月,检测高敏C反应蛋白(hs-CRP)、肌钙蛋白-I(cTn-I),肝肾功能(ALT、AST、Cr)、肌酸激酶(CK)等指标,同时比较两组心血管不良事件(MACE)及药物不良反应发生率。结果两组药物不良反应发生率无统计学差异;A组PCI术后24h、1月hs-CRP值高于B组(P<0.05);术后24h cTn-I值高于B组(P<0.05);术后24h、1月MACE发生率高于B组(P<0.05)。结论围手术期口服大剂量瑞舒伐他汀(20mg/d)可进一步降低老年NSTEMI患者PCI术后hs-CRP、cTn-I值,减少MACE发生率,且用药安全。
Objective To observe the effect of perioperative rosuvastatin on the patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) after PCI. Methods A total of 156 elderly NSTEMI patients scheduled for elective PCI were randomly divided into normal dose (10 mg / d, group A) and high dose (20 mg / d, group B) 78 patients. Before treatment, The levels of hs-CRP, cTn-I, ALT, AST, Cr and creatine kinase (CK) Two groups of cardiovascular adverse events (MACE) and the incidence of adverse drug reactions. Results There was no significant difference in incidence of ADRs between the two groups. The hs-CRP values of 24h and 1h after PCI in group A were higher than those in group B (P <0.05) 0.05). The incidence of MACE at 24h and 1h after operation was higher than that of group B (P <0.05). Conclusion Perioperative oral administration of high dose rosuvastatin (20mg / d) can further reduce the hs-CRP and cTn-I values after PCI in elderly patients with NSTEMI, and reduce the incidence of MACE, and medication safety.